Scarica l'app Stockscreener
1,042.15
1.55%
-16.41
Dopo l'orario di chiusura:
1043.06
0.91
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,058.56
Aprire:
$1042.95
Volume 24 ore:
2.79M
Relative Volume:
0.85
Capitalizzazione di mercato:
$983.12B
Reddito:
$65.18B
Utile/perdita netta:
$20.64B
Rapporto P/E:
46.13
EPS:
22.5894
Flusso di cassa netto:
$5.96B
1 W Prestazione:
+0.59%
1M Prestazione:
-2.08%
6M Prestazione:
+46.44%
1 anno Prestazione:
+18.24%
Intervallo 1D:
$1,024.08
$1,058.90
Intervallo di 1 settimana:
$1,002.46
$1,064.45
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,042.15 | 998.60B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.28 | 592.45B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.44 | 405.58B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
206.61 | 317.72B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
167.11 | 314.27B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly stock price dips after-hours as Zepbound pen news meets Novo’s Wegovy price-cut plan - Bez Kabli
RBC Capital initiates Eli Lilly stock with outperform rating - Investing.com
Eli Lilly vs. Novo Nordisk: A Tale of Two Stocks - InvestorPlace
A Tale of Two Titans: Eli Lilly Surges as Novo Nordisk Stumbles in the Weight Loss Price War - The Chronicle-Journal
Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 - AOL.com
BofA reiterates Eli Lilly stock rating on limited GLP-1 impact - Investing.com
Eli Lilly (LLY) Unaffected by Novo Nordisk's GLP-1 Price Cuts - GuruFocus
Novo Nordisk vs Eli Lilly: Why the ‘king of weight loss’ just lost its crown - The Financial Express
CSL taps Lilly to de-risk IL-6 drug following dismal earnings - BioWorld MedTech
Eli Lilly (LLY) Shares Fall as Novo Nordisk Slashes Drug Prices - GuruFocus
Eli Lilly Strengthens Position in Weight-Loss Drug Market with New Formulation and Clinical Data - AD HOC NEWS
Novo And United’s Triple G Agonist Outpaces Lilly Rival On Weight Loss - Citeline News & Insights
Eli Lilly (LLY) Shares Dip as Novo Nordisk Announces Price Cuts - GuruFocus
Eli Lilly (LLY) Faces Price Competition as Rival Cuts Drug Costs - GuruFocus
Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy - MarketWatch
Eli Lilly: Conservative 2026 Guide, Diversified Pipeline, and Capital Flexibility Underscore Buy Rating Amid Obesity Leadership - TipRanks
Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,260 - 富途牛牛
Eli Lilly Strengthens Lead in Weight-Loss Drug Market - AD HOC NEWS
Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight - Benzinga
How Novo Nordisk Lost Its Lead in the Weight-Loss Market - Bloomberg
Novo-Nordisk A/S's CagriSema has suffered a head-to-head defeat, losing to Eli Lilly and Co's tirzepatide. - 富途牛牛
Eli Lilly's Strategic Momentum: Pipeline Progress and Patient-Centric Innovation - AD HOC NEWS
Is Eli Lilly Stock Underperforming the S&P 500? - Barchart.com
Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs - Yahoo! Finance Canada
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead. - Reuters
Zacks Market Edge Highlights: MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace - The Globe and Mail
Eli Lilly Strengthens Its Lead in the Weight-Loss Drug Arena - AD HOC NEWS
Weight-Loss Drug Rivalry: Novo-Nordisk A/S Suffers Major Defeat Against Eli Lilly and Co, Stock Price Plummets! - 富途牛牛
Lilly gains FDA approval for Zepbound multi-dose KwikPen device By Investing.com - Investing.com Australia
How The Eli Lilly (LLY) Narrative Is Shifting Around Obesity Leadership And Valuation Risks - Yahoo Finance
Top 20 Trading Volume | Apple closed higher against the market trend as five new product launches are imminent; Novo-Nordisk A/S plunged over 16% due to weight-loss drug results falling short of expectations, while Eli Lilly and Co rose nearly 5%; IBM plu - 富途牛牛
Eli Lilly (LLY) Stock Is Up, What You Need To Know - Finviz
Eli Lilly (NYSE:LLY) Development Updates Drive Buzz As S&P 500 Futures - Kalkine Media
Why Novo Nordisk Stock Is Plunging—and Why It’s Good News for Eli Lilly - Barron's
Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal - Finviz
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial - FinancialContent
Why Eli Lilly is suddenly pulling ahead in the GLP-1 weight-loss race - Fast Company
Barclays Begins Coverage on Eli Lilly (LLY), Sees Strong Position in Obesity Market - Finviz
Bullish Sentiment Grows as Eli Lilly (LLY) Sees Surge in Options Activity - GuruFocus
Bloomberg Intelligence: Novo Next-Generation Obesity Shot Falls Short of Lilly Rival - Bloomberg
Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study - BioPharma Dive
Lilly teams up with USOPC to scale Team USA athlete recovery initiative - Campaign US
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound - WSJ
Novo Nordisk's Loss Is Eli Lilly's Gain - Benzinga
Novo Nordisk Stock (NVO) Tumbles in 'Worst Case Scenario'Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO) - Benzinga
Eli Lilly stock jumps as Novo’s obesity-drug trial stumbles — what traders watch next - Bez Kabli
Eli Lilly launches new Zepbound pen with month of doses - Sharecast.com
Eli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market Crash - The Motley Fool
Market news - investments.halifax.co.uk
Eli Lilly (LLY) Gains as FDA Approves Zepbound Label Expansion - GuruFocus
Eli Lilly (LLY) Gains FDA Approval for Enhanced Zepbound Deliver - GuruFocus
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.18%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):